Efavirenz
- Generic Name
- Efavirenz
- Brand Names
- Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C14H9ClF3NO2
- CAS Number
- 154598-52-4
- Unique Ingredient Identifier
- JE6H2O27P8
- Background
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
...
- Indication
For use in combination treatment of HIV infection (AIDS)
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Drug combinations: your questions answered
Developing drug combinations for diseases like cancer faces challenges due to multiple molecular pathways and regulatory hurdles. The FDA and EMA evaluate combinations based on safety and efficacy, with flexibility in initial trials. Dose-ranging and efficacy of individual components are generally expected before codevelopment. Examples of NCE combinations exist, but each case is evaluated based on provided evidence. Computational methods aid in identifying effective combinations and predicting safety, though human safety predictions remain complex.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath